Skip to main content
Figure 2 | Breast Cancer Research

Figure 2

From: Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

Figure 2

Time-dependent assessment of estrogen-related score (ERS) in the high mitosis kinase score (MKS)-group in both tamoxifen-treated and untreated patients. Landmark analyses of the Kaplan-Meier estimates of distant event-free survival (DEFS) for highly proliferative tumors (high-MKS) according to ERS groups (high and low) during the first 2.5 years (left side of each panel), from 2.5 to 5 years (center of each panel) and from 5 to 10 years (right side of each panel) are shown. Results are plotted separately for tamoxifen-treated, node-negative (A), tamoxifen-treated, node-positive (B) and tamoxifen-untreated, node-negative (C) patients.

Back to article page